Rituximab, Anti-CD20, Induces In Vivo Cytokine Release But Does Not Impair Ex Vivo T-Cell Responses-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab, Anti-CD20, Induces In Vivo Cytokine Release But Does Not Impair Ex Vivo T-Cell Responses

Published:2004-08 Issue:8 Volume:4 Page:1357-1360
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Agarwal Avinash,Vieira Carlos A.,Book Benita K.,Sidner Richard A.,Fineberg N. S.,Pescovitz Mark D.

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-6143.2004.00502.x/fullpdf

Reference20 articles.

1. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production.

2. REMOVAL OF LYMPHOCYTOTOXIC ANTIBODIES BY PRETRANSPLANT IMMUNOADSORPTION THERAPY IN HIGHLY SENSITIZED RENAL TRANSPLANT RECIPIENTS

3. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match

4. Rituximab: clinical development and future directions

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab induces a flare-up of activated neutrophil extracellular traps under in vitro conditions;Immunopharmacology and Immunotoxicology;2022-07-11

2. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials;Expert Opinion on Emerging Drugs;2022-04-03

3. Advancing Biologic Therapy for Refractory Autoimmune Hepatitis;Digestive Diseases and Sciences;2022-02-11

4. COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus;Dermatologic Therapy;2021-12

5. CTOTC‐08: A multicenter randomized controlled trial of rituximab induction to reduce antibody development and improve outcomes in pediatric lung transplant recipients;American Journal of Transplantation;2021-11-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3